lanifibranor
Small moleculeexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02503644)
Timeline
Indications
Mechanism of action
PPARD activator
PPARA activator
PPARG activator
Peroxisome proliferator-activated receptor agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1- Mol. weight
- 434.93 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4091374 ↗
Also known as
- iva337
- iva337
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06126562 | Phase 1 | Oct 31, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05232071 | Phase 2 | Jun 29, 2022 | Inventiva Pharma |
| NCT04849728 | Phase 3 | Aug 19, 2021 | Inventiva Pharma, University of Antwerp, Virginia Commonwealth University |
| NCT03866369 | Phase 1 | Jan 17, 2019 | Inventiva Pharma, Parexel |
| NCT03459079 | Phase 2 | Aug 14, 2018 | Inventiva Pharma, University of Florida |
| NCT03008070 | Phase 2 | Dec 1, 2016 | Inventiva Pharma, University of Antwerp |
| NCT02503644 | Phase 2 | Oct 1, 2015 | Inventiva Pharma, University of London |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inventiva Pharma | For profit | 6 | 5 | 3 | 2015 |
| University of Antwerp | Academic/Hospital | 2 | 0 | 2 | 2016 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 1 | 1 | 1 | 2023 |
| Parexel | For profit | 1 | 0 | 1 | 2019 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1